eligibility_summary
Adults ≥18 with ECOG 0–2, ≥12‑wk survival, untreated CD20+ marginal zone lymphoma (splenic/nodal/extranodal) requiring therapy, measurable disease on CT/MRI, adequate organ function, contraception, and consent. Exclude CNS involvement, other active cancer, major cardiac disease (QTc↑, NYHA III–IV, LVEF<50%), coagulopathy/anticoag, recent thrombosis, major surgery/trauma <4 wks, malabsorption, active infection or HBV/HCV, substance/psychiatric issues, recent trials, strong CYP3A4 meds, pregnancy/lactation, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06700798: Randomized, open-label phase II in untreated marginal zone lymphoma comparing orelabrutinib+rituximab (OR-R) vs R-CVP. Orelabrutinib is an oral, second-generation covalent BTK inhibitor (small molecule) that blocks B-cell receptor signaling, suppressing NF-κB/PI3K-AKT/MAPK pathways to reduce proliferation/survival of malignant B cells. Rituximab is an anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis. R-CVP adds cyclophosphamide (alkylating DNA crosslinker), vincristine (vinca alkaloid microtubule inhibitor causing mitotic arrest), and prednisone (glucocorticoid inducing lymphocyte apoptosis, anti–NF-κB). Targets: CD20+ marginal zone B cells, BTK/BCR signaling and downstream survival pathways, DNA replication/mitotic spindle, glucocorticoid receptor signaling. OR-R includes orelabrutinib maintenance, R-CVP includes rituximab maintenance.